Bristol BuSpar Metabolite Patent Issued One Day Before Watson Generic
Bristol-Myers Squibb's last-minute patent listing for BuSpar is based on the discovery of an anxiolytic action for a buspirone metabolite.
Bristol-Myers Squibb's last-minute patent listing for BuSpar is based on the discovery of an anxiolytic action for a buspirone metabolite.